{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:12:05Z","timestamp":1793398325143,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02069-1","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T09:40:40Z","timestamp":1747302040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prevalence, disability, and economic impact of migraine in Spain: a nationwide population-based study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7724-2890","authenticated-orcid":false,"given":"Margarita","family":"Sanchez-del-Rio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garc\u00eda-Azor\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Peral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Armada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Irimia-Sieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7034-682X","authenticated-orcid":false,"given":"Jesus","family":"Porta-Etessam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"2069_CR1","doi-asserted-by":"crossref","unstructured":"Steiner T, Stovner L, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. BioMed Central. 21:1\u20134","DOI":"10.1186\/s10194-020-01208-0"},{"issue":"10440","key":"2069_CR2","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"AJ Ferrari","year":"2024","unstructured":"Ferrari AJ, Santomauro DF, Aali A, Abate YH, Abbafati C, Abbastabar H, Abd ElHafeez S, Abdelmasseh M, Abd-Elsalam S, Abdollahi A (2024) Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet 403(10440):2133\u20132161","journal-title":"Lancet"},{"issue":"1","key":"2069_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-024-01798-z","volume":"25","author":"J Cen","year":"2024","unstructured":"Cen J, Wang Q, Cheng L, Gao Q, Wang H, Sun F (2024) Global, regional, and National burden and trends of migraine among women of childbearing age from 1990 to 2021: insights from the global burden of disease study 2021. J Headache Pain 25(1):96","journal-title":"J Headache Pain"},{"issue":"8","key":"2069_CR4","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM, Lipton RB (2019) Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache: J Head Face Pain 59(8):1286\u20131299","journal-title":"Headache: J Head Face Pain"},{"issue":"1","key":"2069_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40122-024-00690-7","volume":"14","author":"L Dong","year":"2025","unstructured":"Dong L, Dong W, Jin Y, Jiang Y, Li Z, Yu D (2025) The global burden of migraine: A 30-Year trend review and future projections by age, sex, country, and region. Pain Therapy 14(1):297\u2013315","journal-title":"Pain Therapy"},{"issue":"1","key":"2069_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10194-024-01740-3","volume":"25","author":"D Garc\u00eda-Azor\u00edn","year":"2024","unstructured":"Garc\u00eda-Azor\u00edn D, Moya-Alarc\u00f3n C, Armada B, S\u00e1nchez Del R\u00edo M (2024) Societal and economic burden of migraine in Spain: results from the 2020 National health and wellness survey. J Headache Pain 25(1):38","journal-title":"J Headache Pain"},{"issue":"1","key":"2069_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12889-024-21244-8","volume":"25","author":"G Coppola","year":"2025","unstructured":"Coppola G, Brown JD, Mercadante AR, Drakeley S, Sternbach N, Jenkins A, Blakeman KH, Gendolla A (2025) The epidemiology and unmet need of migraine in five European countries: results from the National health and wellness survey. BMC Public Health 25(1):254","journal-title":"BMC Public Health"},{"issue":"12","key":"2069_CR8","doi-asserted-by":"publisher","first-page":"033310242412764","DOI":"10.1177\/03331024241276415","volume":"44","author":"A Gendolla","year":"2024","unstructured":"Gendolla A, Brown JD, Mercadante AR, Drakeley S, Sternbach N, Jenkins A, Hygge Blakeman K, Coppola G (2024) The incremental burden and healthcare resource utilization among people with migraine in Europe: insights from the 2020 European National health and wellness survey. Cephalalgia: Int J Headache 44(12):03331024241276415","journal-title":"Cephalalgia: Int J Headache"},{"issue":"1","key":"2069_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/sjmms.sjmms_95_22","volume":"11","author":"S Aditya","year":"2023","unstructured":"Aditya S, Rattan A (2023) Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review. Saudi J Med Med Sci 11(1):11\u201318","journal-title":"Saudi J Med Med Sci"},{"issue":"1","key":"2069_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-023-01637-7","volume":"24","author":"J Schoenen","year":"2023","unstructured":"Schoenen J, Van Dycke A, Versijpt J, Paemeleire K (2023) Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review. J Headache Pain 24(1):99","journal-title":"J Headache Pain"},{"issue":"1","key":"2069_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Ulud\u00fcz D, Versijpt J, Ducros A, Gil-Gouveia R, Katsarava Z et al (2022) European headache federation (EHF) consensus on the definition of effective treatment of a migraine attack and of Triptan failure. J Headache Pain 23(1):133","journal-title":"J Headache Pain"},{"key":"2069_CR12","doi-asserted-by":"crossref","unstructured":"Belv\u00eds R, Irimia P, Gonz\u00e1lez N, Garc\u00eda-Ull J, Pozo-Rosich P, L\u00f3pez-Bravo A, Moroll\u00f3n N, Quintas S, Plana A, Baz PG et al (2024) Documento de consenso de la Sociedad Espa\u00f1ola de Neurolog\u00eda (SEN), Sociedad Espa\u00f1ola de Medicina de Familia y Comunitaria (SEMFYC), Sociedad de Medicina de Atenci\u00f3n Primaria (SEMERGEN) y Asociaci\u00f3n Espa\u00f1ola de Migra\u00f1a y Cefalea (AEMICE) sobre el tratamiento de la migra\u00f1a. Medicina Cl\u00ednica 163(4):208.e201-208.e210","DOI":"10.1016\/j.medcli.2024.02.006"},{"key":"2069_CR13","unstructured":"BIFIMED [https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetallecn=723375]"},{"issue":"5","key":"2069_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"issue":"suppl1","key":"2069_CR15","first-page":"S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 56(suppl1):S20\u2013S28","journal-title":"Neurology"},{"issue":"1","key":"2069_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-9-12","volume":"9","author":"A Montazeri","year":"2011","unstructured":"Montazeri A, Vahdaninia M, Mousavi SJ, Asadi-Lari M, Omidvari S, Tavousi M (2011) The 12-item medical outcomes study short form health survey version 2.0 (SF-12v2): a population-based validation study from Tehran, Iran. Health Qual Life Outcomes 9(1):1\u20138","journal-title":"Health Qual Life Outcomes"},{"key":"2069_CR17","unstructured":"Maruish M (2011) User\u2019s Manual for the SF-36v2 Health Survey,; QualityMetric. Inc: Lincoln, RI, USA"},{"key":"2069_CR18","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727\u20131736","journal-title":"Qual Life Res"},{"key":"2069_CR19","unstructured":"Ware JE, Keller SD, Kosinski M (1995) SF-12: how to score the SF-12 physical and mental health summary scales. Health Institute, New England Medical Center"},{"issue":"9","key":"2069_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16(9):606\u2013613","journal-title":"J Gen Intern Med"},{"key":"2069_CR21","doi-asserted-by":"crossref","unstructured":"Thompson SG, Barber JA (2000) How should cost data in pragmatic randomised trials be analysed? Bmj. 320(7243):1197\u20131200","DOI":"10.1136\/bmj.320.7243.1197"},{"issue":"4","key":"2069_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/0333102410382794","volume":"31","author":"J Mat\u00edas-Guiu","year":"2011","unstructured":"Mat\u00edas-Guiu J, Porta-Etessam J, Mateos V, D\u00edaz-Insa S, Lopez-Gil A, Fern\u00e1ndez C (2011) One-year prevalence of migraine in Spain: a nationwide population-based survey. Cephalalgia: Int J Headache 31(4):463\u2013470","journal-title":"Cephalalgia: Int J Headache"},{"issue":"1","key":"2069_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12883-024-03600-8","volume":"24","author":"P Pozo-Rosich","year":"2024","unstructured":"Pozo-Rosich P, Carmo M, Mu\u00f1iz A, Armada B, Moya-Alarc\u00f3n C, Pascual J (2024) Migraine treatment: quo vadis? Real-world data study (2015\u20132022) in Spain. BMC Neurol 24(1):107","journal-title":"BMC Neurol"},{"key":"2069_CR24","doi-asserted-by":"crossref","unstructured":"Irimia P, Belv\u00eds R, Garc\u00eda Gonz\u00e1lez N, Garc\u00eda Ull J, La\u00ednez JM (2023) Inequity of access to new migraine treatments. Neurologia 38(8):599\u2013600","DOI":"10.1016\/j.nrleng.2022.08.004"},{"key":"2069_CR25","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.nrl.2021.10.012","volume":"38","author":"S D\u00edaz-Insa","year":"2023","unstructured":"D\u00edaz-Insa S, Navarro-Zornoza M, S\u00e1nchez-de la Rosa R, Guerrero AL (2023) Caracterizaci\u00f3n Del Manejo Del Paciente Con Migra\u00f1a En Atenci\u00f3n primaria En Espa\u00f1a. An\u00e1lisis de Los resultados Del proyecto Europeo My-LIFE anamnesis. Neurolog\u00eda 38:S22\u2013S30","journal-title":"Neurolog\u00eda"},{"issue":"5","key":"2069_CR26","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s40122-023-00538-6","volume":"12","author":"J Pascual","year":"2023","unstructured":"Pascual J, N\u00fa\u00f1ez M, Panni T, D\u00edaz-Cerezo S, Novick D, Ciudad A (2023) Burden and unmet needs in migraine patients: results from the OVERCOME (Spain) study. Pain Ther 12(5):1209\u20131220","journal-title":"Pain Ther"},{"issue":"6","key":"2069_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/14656566.2024.2349791","volume":"25","author":"L Pellesi","year":"2024","unstructured":"Pellesi L, Do TP, Hougaard A (2024) Pharmacological management of migraine: current strategies and future directions. Expert Opin Pharmacother 25(6):673\u2013683","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"2069_CR28","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1007\/s10072-022-06178-6","volume":"43","author":"MF Rossi","year":"2022","unstructured":"Rossi MF, Tumminello A, Marconi M, Gualano MR, Santoro PE, Malorni W, Moscato U (2022) Sex and gender differences in migraines: a narrative review. Neurol Sci 43(9):5729\u20135734","journal-title":"Neurol Sci"},{"key":"2069_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10194-009-0176-5","volume":"11","author":"C Fern\u00e1ndez-de-Las-Pe\u00f1as","year":"2010","unstructured":"Fern\u00e1ndez-de-Las-Pe\u00f1as C, Hern\u00e1ndez-Barrera V, Carrasco-Garrido P, Alonso-Blanco C, Palacios-Cena D, Jim\u00e9nez-S\u00e1nchez S, Jim\u00e9nez-Garc\u00eda R (2010) Population-based study of migraine in Spanish adults: relation to socio-demographic factors, lifestyle and co-morbidity with other conditions. J Headache Pain 11:97\u2013104","journal-title":"J Headache Pain"},{"issue":"Suppl 2","key":"2069_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10072-020-04643-8","volume":"41","author":"G Allais","year":"2020","unstructured":"Allais G, Chiarle G, Sinigaglia S, Airola G, Schiapparelli P, Benedetto C (2020) Gender-related differences in migraine. Neurol Sci 41(Suppl 2):429\u2013436","journal-title":"Neurol Sci"},{"issue":"1","key":"2069_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40122-024-00686-3","volume":"14","author":"T Alsaadi","year":"2025","unstructured":"Alsaadi T, Al Madani A, Alhatou M, Nada M, Albilali A, Al-Qassabi A, Mohamed H, Mohamed H, El Masry R, Saifuddin GA et al (2025) Prevalence, treatment, and unmet needs of migraine in the middle East: A systematic review. Pain Therapy 14(1):145\u2013183","journal-title":"Pain Therapy"},{"issue":"11","key":"2069_CR32","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1212\/WNL.0b013e3182a43b32","volume":"81","author":"WF Stewart","year":"2013","unstructured":"Stewart WF, Roy J, Lipton RB (2013) Migraine prevalence, socioeconomic status, and social causation. Neurology 81(11):948\u2013955","journal-title":"Neurology"},{"key":"2069_CR33","unstructured":"L\u00e1inez Andr\u00e9s INFORME Depresi\u00f3n y Neurolog\u00eda. Sociedad Espa\u00f1ola de Neurolog\u00eda, LXXIV Reuni\u00f3n Annual de la SEN, Sevilla, del 15 al 19 de noviembre de 2022"},{"key":"2069_CR34","doi-asserted-by":"publisher","unstructured":"Rub\u00e9n Roy E, S\u00e1nchez-Rodr\u00edguez S, Gal\u00e1n M\u00e9lanie, Racine E, Castarlenas MP, Jensen Jordi Mir\u00f3: factors associated with migraine in the general population of Spain: results from the European health survey 2014, pain medicine, 20, issue 3, March 2019, Pages 555\u2013563, https:\/\/doi.org\/10.1093\/pm\/pny093","DOI":"10.1093\/pm\/pny093"},{"issue":"12","key":"2069_CR35","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/brainsci13121630","volume":"13","author":"Jes\u00fas Cebrino","year":"2023","unstructured":"Cebrino Jes\u00fas, Silvia Portero de la Cruz (2023) Prevalence and associated factors of depression among adults suffering from migraine in Spain. Brain Sci 13(12):1630","journal-title":"Brain Sci"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02069-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02069-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02069-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T09:40:47Z","timestamp":1747302047000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02069-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2069"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02069-1","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The NHWS received approval from the Pearl Institutional Review Board. All the NHWS respondents provided informed consent electronically prior to their participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Within the past 24 months, Dr. Garc\u00eda-Azor\u00edn has received personal compensation for consulting\/advising from the World Health Organization. Nonprofit board membership in the Spanish Society of Neurology, and the European Union of Medical Specialist section of Neurology. Research funding from the Regional Health Administration (Gerencia Regional de Salud SACYL) in Castilla y Leon, Carlos III Institute of Spain, and Eli Lilly. Speaker\/travel grants\/ clinical trials participation for Teva, Allergan\/Abbvie, Amgen, Eli Lilly, Lundbeck, Novartis, and Biohaven. BA and CP are Pfizer employees. Within the past 24 months MSdR is the second vicepresident of the European Headache Federation. She has received personal fees as Speaker from Teva, Pfizer, Eli Lilly, Lundbeck and Organon.Within the past 24 months, Dr. Pablo Irimia has received personal fees for Speaker\/travel grants from Teva, Allergan\/Abbvie, Eli Lilly, Organon, Lundbeck, Novartis, and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}